There is no single A1C number that qualifies you for Ozempic. The FDA approval is based on having a diagnosis of type 2 diabetes, not on hitting a specific A1C threshold. In practice, though, your A1C matters quite a bit because insurance companies and clinical guidelines use it to decide when this medication makes sense and whether they’ll pay for it.
What the FDA Actually Requires
Ozempic is approved as an add-on to diet and exercise for adults with type 2 diabetes. The prescribing label doesn’t mention a minimum or maximum A1C. If you have a confirmed type 2 diabetes diagnosis, you’re technically eligible from a regulatory standpoint.
That said, the label includes an important limitation: Ozempic is not recommended as a first-line therapy for people whose blood sugar isn’t adequately controlled through diet and exercise alone. This means most prescribers treat it as a second step, not the first thing you try after diagnosis.
What Insurance Companies Look For
This is where specific A1C numbers come into play. Most insurance plans require prior authorization before they’ll cover Ozempic, and the criteria are more concrete than the FDA label. A prior authorization form from Johns Hopkins Health Plans, which is representative of many commercial insurers, asks whether the patient has an A1C of 6.5% or higher, the standard diagnostic cutoff for type 2 diabetes.
Beyond confirming your diagnosis, insurers typically want to see that you’ve already tried metformin. The common requirement is an inadequate response to at least three months of optimally dosed metformin, or a documented contraindication to it. If you haven’t tried metformin first (or can’t tolerate it), most plans will deny the claim. This step-therapy requirement is the biggest hurdle for many people, sometimes more so than the A1C number itself.
Coverage criteria vary by plan. Some require a higher starting A1C (such as 7% or above) to demonstrate that existing treatment isn’t working well enough. Others may approve it at 6.5% if metformin has failed. Calling your insurer or checking your plan’s formulary is the most reliable way to find out your specific requirements.
What Clinical Guidelines Recommend
The American Association of Clinical Endocrinology (AACE) and the American Diabetes Association (ADA) both position GLP-1 medications like Ozempic within their treatment algorithms based on A1C ranges. For people newly diagnosed with type 2 diabetes whose A1C is 7.5% or higher, the 2023 AACE guidelines suggest starting a GLP-1 medication alongside metformin from the beginning, rather than waiting to see if metformin alone is enough.
For A1C levels between 6.5% and 7.5%, guidelines generally recommend starting with metformin or another first-line drug and adding a GLP-1 only if targets aren’t met after a few months. So while there’s no hard cutoff, an A1C of 7.5% or above gives your doctor a stronger clinical rationale to prescribe Ozempic early in treatment.
Can You Get Ozempic for Prediabetes?
Prediabetes falls in the A1C range of 5.7% to 6.4%, and there are currently no FDA-approved medications specifically for prediabetes. Some doctors do prescribe Ozempic off-label for prediabetes or weight management, but this comes with significant practical barriers. Medicare does not cover Ozempic for prediabetes, and most commercial insurers follow the same policy. You’d likely pay out of pocket, which can run over $1,000 per month without coverage.
Early research on semaglutide (the active ingredient in Ozempic) for prediabetes has shown promise, but the evidence isn’t strong enough yet for widespread recommendations.
Ozempic vs. Wegovy: Different Criteria
Ozempic and Wegovy contain the same drug, semaglutide, but are approved for different purposes. Ozempic is a diabetes medication, so eligibility revolves around your A1C and diabetes diagnosis. Wegovy is approved for chronic weight management and uses BMI-based criteria instead: a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure or high cholesterol. Wegovy doesn’t require a diabetes diagnosis or any particular A1C level. If your primary goal is weight loss and you don’t have type 2 diabetes, Wegovy is the version designed for that purpose.
How Quickly A1C Drops on Ozempic
Once you start Ozempic, blood sugar levels begin declining within the first week, though the early changes are small. The full effect on A1C typically takes about 12 weeks of consistent dosing, since A1C reflects your average blood sugar over roughly three months. Across major clinical trials, semaglutide reduced A1C by 0.6 to 1.6 percentage points compared to placebo, depending on dosage and baseline levels. Someone starting at an A1C of 9%, for example, might see it drop to the mid-7s or lower.
Most doctors recheck your A1C about three months after starting treatment, then every six months once levels stabilize. The medication is dosed gradually, starting low and increasing over several weeks, so meaningful results take time even though some blood sugar improvement begins right away.
Putting It Together
If your A1C is 6.5% or above and you have a type 2 diabetes diagnosis, you meet the basic medical criteria for Ozempic. Getting it covered by insurance usually requires an A1C at or above 6.5%, proof that metformin didn’t work or isn’t an option, and prior authorization paperwork from your prescriber. An A1C of 7.5% or higher strengthens your case under current clinical guidelines, since that’s the level where major medical organizations recommend adding a GLP-1 medication early in treatment rather than waiting.